Article
RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Apr 2011
Gaidzik Verena I, Bullinger Lars, Schlenk Richard F, Zimmermann Andreas S, Röck Jürgen, Paschka Peter, Corbacioglu Andrea, Krauter Jürgen, Schlegelberger Brigitte, Ganser Arnold, Späth Daniela, Kündgen Andrea, Schmidt-Wolf Ingo G H, Götze Katharina, Nachbaur David, Pfreundschuh Michael, Horst Heinz A, Döhner Hartmut, Döhner Konstanze
Abstract excerpt
PURPOSE: To evaluate frequency, biologic features, and clinical relevance of RUNX1 mutations in acute myeloid leukemia (AML). PATIENTS AND METHODS: Diagnostic samples from 945 patients (age 18 to 60 years) were analyzed for RUNX1 mutations. In a subset of cases (n = 269), microarray gene expression analysis was performed. RESULTS: Fifty-nine RUNX1 mutations were identified in 53 (5.6%) of 945 cases, predominantly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
